Mature results of a phase I/IIA trial of the integrin inhibitor cilengitide (EMD121974) added to standard concomitant and adjuvant temozolomide and radiotherapy (TMZ/RT) for newly diagnosed glioblastoma (GBM)
NEURO-ONCOLOGY（2007）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要